Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 25, 2020
Context: The Company reported the entry into a material definitive agreement regarding the exercise of existing warrants and the issuance of new warrants following a public offering completed in December 2019.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.9 million expected from the exercise of 4,000,000 Existing Warrants.
- Transaction Fees: $343,000 payable to the placement agent, plus reimbursements for legal fees and other expenses.
- Placement Agent Compensation: A new warrant to purchase 200,000 shares of Common Stock (5.0% of the New Warrants issued).
- Exercise Price (Existing Warrants): $1.10 per share.
- Effective Price Paid by Holder: $1.225 per share (covering the $1.10 exercise price and $0.125 purchase price for New Warrants).
- New Warrants Exercise Price: $1.27 per share.
- Warrant Term: 5.5 years, exercisable immediately.
Material Changes and Transaction Structure
On March 25, 2020, the Company entered into an Exercise Agreement with a holder of Existing Warrants. The transaction involved:
- Exercise of Existing Warrants: The holder exercised the remaining 4,000,000 Existing Warrants (out of 4,139,477 originally issued in the December Offering).
- Issuance of New Warrants: In connection with the exercise, the Company issued 4,000,000 New Warrants to purchase Common Stock.
- Registration Status: The New Warrants and underlying shares are unregistered, offered under Section 4(a)(2) or Rule 506(b) exemptions. The Company is required to register the shares for resale.
- Cashless Exercise Provision: New Warrants include a cashless exercise option if a resale registration statement is not effective after six months.
Outlook, Risks, and Management Commentary
Management Commentary: The filing confirms the completion of the warrant exercise process initiated in the December 2019 offering. The Company expects to receive the gross proceeds noted above, net of fees and expenses.
Risks and Contingencies:
- Registration Risk: The ability to exercise New Warrants for cash depends on the effectiveness of a resale registration statement; otherwise, the holder may be limited to cashless exercise.
- Dilution: The issuance of 4,000,000 New Warrants and the underlying shares upon exercise represents potential dilution to existing shareholders.
Key Facts for Investor Verification
- Verify the net cash proceeds after deducting the $343,000 placement fee and other reimbursable expenses.
- Confirm the total number of shares outstanding post-exercise of the 4,000,000 Existing Warrants.
- Monitor the status of the resale registration statement required for the New Warrants to ensure cash exercise capability.
- Review the impact of the 200,000 placement agent warrants on future dilution.